ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: Weinstein Names Permanent Director Of Columbia Comprehensive Center; Gottsman Heads Institute

February 8, 1985

Lurie Center At Northwestern Wins Core Grant Renewal.

December 7, 2001

Intermittent Androgen Deprivation Therapy Not Equal to Continuous Treatment, Study Finds

April 26, 2013

In Brief: Wells, Gardner, Brennan Lead Surgical Oncology; Young, Flynn, Are New officers For Head & Neck

March 26, 1993

Long-Term Estrogen Use May Increase Ovarian Cancer Risk

April 27, 2001

NCI Forms New Committees to Oversee Cancer Clinical Trials.

February 17, 2006